Enveric Biosciences ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announces the ...

(Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a co-marketing and sales agreement with Thermo Fisher Scientific, the world ...

Seer also announced a co-marketing and sales agreement with Thermo Fisher Scientific to jointly promote Proteograph alongside ...

As of early 2024, Thermo Fisher carried roughly $36 billion in long- and short-term obligations. The PPD acquisition materially increased its leverage (2.6 debt/EBITDA for 2023) but we anticipate this ...

DUBLIN--(BUSINESS WIRE)--The "European Life Science Tools and Reagents Market" report has been added to ResearchAndMarkets.com's offering. The European market for life science tools and reagents and ...

I am upgrading Thermo Fisher Scientific Inc. to a “Buy” with a fair value of $610 per share due to anticipated recovery in the pharma and biotech industries. Thermo Fisher's high-impact ...

The US Food and Drug Administration granted clearances for various tests for infectious diseases, coagulation disorders, and drug susceptibility.

On Wednesday, Thermo Fisher Scientific Inc. (NYSE: TMO) posted third-quarter revenue of $10.59 billion, almost flat year over year, marginally missing the consensus of $10.64 billion. Revenue ...

Oct 23 (Reuters) - Thermo Fisher Scientific (TMO.N), opens new tab on Wednesday raised the lower end of its annual profit forecast, tweaking it for the third time this year, betting on improved ...

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2024 third quarter conference call. My name is Ezra, and I will be your coordinator today. [Operator instructions] I ...